Linda M S Resar

Outcome heterogeneity in CALR ‐mutated myeloproliferative neoplasms

Summary Calreticulin gene ( CALR ) mutations are seen in 25%–30% of myeloproliferative neoplasms (MPNs). We report outcomes and high‐risk genomic signatures in 149 patients with CALR‐mutated MPN. CALR‐mutated essential thrombocythaemia ( n = 106) progressed to myelofibrosis ( n =...

HMGA1 and HMGA2: epigenetic regulators in myeloproliferative neoplasms and novel platelet transcriptomic biomarkers of myelofibrosis

We read with great interest two recent studies by Handa et al. [ 1 ] and Bartalucci et al. [ 2 ] reporting novel chromosomal deletions within the 3’ untranslated region (UTR) of HMGA2 (Δ3’ HMGA2 ) in myeloproliferative neoplasms (MPNs). Both teams identified submicroscopic deleti...